In Focus channel feed

Cash, chips and tal­ent: In­side Nvidi­a's plan to dom­i­nate biotech's AI rev­o­lu­tion

Last year
R&D
AI

With GIP, obe­si­ty re­search is at odds

Last year
R&D

The US could up­end bio­phar­ma man­u­fac­tur­ing. WuXi ri­vals have an open­ing

Last year
China
Manufacturing

Fe­male in­vestors track progress, call for more women on boards and in lead­er­ship roles

Last year
People
Financing

WuXi be­came a crit­i­cal part­ner to bio­phar­ma com­pa­nies. They’re not ready if the US cracks down

Last year
Deals
China

Star­tups raised mil­lions to in-li­cense drugs to Chi­na. Then the mod­el fell apart

Last year
Deals
China

Amy­lyx read­ies for make-or-break PhI­II, look­ing to ad­dress un­cer­tain­ty over con­tro­ver­sial ALS drug

Last year
R&D
Pharma

Fail­ure, faith and $8 bil­lion: How Lil­ly's amy­loid con­vic­tion brought it to the brink of Alzheimer's ap­proval

Last year
Pharma

Once a sci­en­tif­ic back­wa­ter, pro­tein re­search at­tracts bil­lion-dol­lar deals and high-pro­file pub­li­ca­tions

Last year
Discovery
Diagnostics

'Obe­si­ty plus': What’s next for GLP-1s?

Last year
R&D

In clash over sci­ence and na­tion­al se­cu­ri­ty, Chi­nese ri­val to Il­lu­mi­na strug­gles with US ex­pan­sion

Last year
China
Diagnostics

A sweep­ing form of search-and-re­place edit­ing has come for mR­NA

Last year
R&D

The aca­d­e­m­ic-en­tre­pre­neur mod­el built com­pa­nies and mint­ed mil­lion­aires. What hap­pens when one of its ear­li­est ad­vo­cates quits?  

Last year
People
Startups

Lutetium, ac­tini­um or lead: Can iso­tope type of­fer an edge in ra­dio­ther­a­py?

Last year
Manufacturing

'If you could have the next Prozac, that’s in­tox­i­cat­ing': Sage’s post­par­tum de­pres­sion tri­umph and the fail­ure that fol­lowed

Last year
R&D
Pharma

Roger Perl­mut­ter lights up the bi­o­log­i­cal dark, build­ing a new phar­ma force in Eikon and its su­per­pow­ered mi­cro­scopes

Last year
Startups
R&D

Grail has big plans for its blood can­cer tests. The first step: Find­ing a new own­er

Last year
Diagnostics

Why 2023 was the year of un­so­licit­ed ac­qui­si­tion bids — and why next year like­ly won’t be

Last year
Deals

Lil­ly, No­vo’s bet on heart dis­ease starts to take shape, and 2024 could be a piv­otal year for their GLP-1s 

Last year
R&D

How one lab's decades­long search for the 'holy grail' of sick­le cell led to the first CRISPR ther­a­py

Last year
R&D
Cell/Gene Tx

Aviv Regev leads Genen­tech's next rev­o­lu­tion with AI

Last year
R&D
AI

Up­dat­ed: Will the UK’s triple-pronged ap­proach ease pric­ing, reg­u­la­to­ry and fi­nan­cial bot­tle­necks?

Last year
Pharma

Ful­ly syn­thet­ic genome nears com­ple­tion in a step to­ward un­rav­el­ing ge­net­ic mys­ter­ies

Last year
R&D
Discovery

mR­NA’s next trick? Re­pro­gram­ming off-the-shelf cell ther­a­pies for can­cer and au­toim­mune dis­eases

Last year
Cell/Gene Tx
First page Previous page 123456 Next page Last page
A service from the Financial Times